Key Takeaways
- Fraud Probe: UnitedHealth (UNH) faces a DOJ criminal probe over alleged Medicare Advantage fraud, which it denies.
- Stock Crash: Its stock has plunged 49% in 2025, wiping out over $300 billion in market value.
- Leadership Crisis: CEO resignation, rising costs, and leadership instability deepen the company’s ongoing crisis.
DOJ Probe Sparks Stock Plunge
Shares of UnitedHealth Group fell nearly 13% on Thursday following a Wall Street Journal report that the U.S. Department of Justice has launched a criminal investigation into the company’s Medicare Advantage business over potential fraud. The DOJ has reportedly been investigating the company since last summer, though it has not officially informed UnitedHealth. The company strongly pushed back, stating, “We have not been notified by the Department of Justice of the supposed criminal investigation reported, without official attribution, in the Wall Street Journal today.” It also added, “We stand by the integrity of our Medicare Advantage program.”
This is the second time this year the company’s Medicare practices have come under scrutiny—earlier in February, a civil investigation was reported regarding inflated diagnoses used to generate higher Medicare payments. Additionally, Senator Chuck Grassley launched an inquiry into the company’s billing practices. Medicare is a government-run health program for elderly and disabled Americans, while Medicare Advantage is a private insurance alternative where firms like UnitedHealth contract with the government to provide benefits. The Medicare and retirement segment, which includes Medicare Advantage, is UnitedHealth’s largest revenue driver, generating $139 billion in sales last year.
Market Value Wiped Out
The investigation adds to a series of blows that have severely impacted UnitedHealth’s financial standing. The company’s market value has plunged by more than $300 billion since November, dropping from $600 billion as shares tumbled to $267 levels not seen in five years. UnitedHealth is now the worst-performing component of the Dow Jones Industrial Average in 2025, with shares down approximately 49% year-to-date. Analysts like Jared Holz of Mizuho and James Harlow of Novare Capital warn that if instability continues, the company could face removal from the Dow.
It has been a punishing period for UnitedHealth, beginning in December when executive Brian Thompson was targeted and killed outside a New York City hotel. Combined with a historic cyberattack and rising medical costs, the company’s stability has been repeatedly tested. Earlier this week, UnitedHealth announced it would suspend its full-year financial outlook due to those higher-than-expected costs, compounding investor anxiety.
Leadership Shake-Up and Future Outlook
Amid these challenges, CEO Andrew Witty abruptly resigned for personal reasons and was replaced by former chief executive Stephen Hemsley in a bid to restore stability and investor confidence. The leadership transition followed UnitedHealth’s withdrawal of its 2025 forecast, which triggered an additional 18% plunge in shares to a four-year low earlier in the week.
Despite the wave of setbacks, some analysts remain cautiously optimistic. Oppenheimer’s Michael Wiederhorn noted that while the company’s fundamentals are solid, it will take time to regain trust in the market. As scrutiny from regulators, lawmakers, and investors intensifies, the focus now shifts to how UnitedHealth navigates the road ahead.
Market Update Into September 7th: Inflation Data Incoming